Having demonstrated the uptake of siRNAs by the specific cell type of interest, we further determined their ability to specifically knockdown the endogenous (over)expression of KDR, which is a hallmark of portal hypertension that contributes to disease progression and aggravation6–12. The gene discussed is KDR; the disease is liver disorder.